Extrapyramidal side effects (EPS) encompass four clinically distinct syndromes produced by dopamine (DA) D2 receptor blockade in the nigrostriatal pathway: acute dystonia, akathisia, drug-induced parkinsonism (DIP), and tardive dyskinesia (TD). The first three are acute to subacute in onset and generally reversible with dose reduction, agent switching, or pharmacological intervention. Tardive dyskinesia is a late-onset, potentially irreversible syndrome addressed separately in Section 2.
Acute dystonic reactions are involuntary, sustained muscle contractions producing abnormal postures, typically affecting the neck (torticollis), jaw (trismus), tongue (glossospasm), eyes (oculogyric crisis), or trunk (opisthotonus). They occur within hours to days of initiating a high-potency first-generation antipsychotic (FGA) or, less commonly, after dose escalation, and are more prevalent in young males, patients naive to antipsychotics, and those receiving high-potency agents.1 The mechanism involves a relative excess of cholinergic tone in the striatum secondary to acute D2 blockade, disrupting the normal balance between dopaminergic inhibition and cholinergic excitation of striatal neurons.
Treatment of acute dystonia is immediate anticholinergic administration: benztropine 1 to 2 mg or diphenhydramine 25 to 50 mg, given intramuscularly (IM) or intravenously (IV) for rapid effect, produces resolution within minutes in most cases. Oral continuation for several days after an acute episode prevents recurrence during the period of highest risk. Prophylactic anticholinergic therapy is reasonable for patients starting high-potency FGAs, particularly young males with no prior antipsychotic exposure, though routine prophylaxis in all patients introduces its own anticholinergic burden and is not universally recommended.1
Akathisia is a subjective sense of inner restlessness accompanied by an irresistible urge to move, typically manifesting as inability to sit still, pacing, leg crossing and uncrossing, and foot tapping. It is the most clinically underrecognized EPS syndrome because patients may not report it spontaneously, because it can be mistaken for psychotic agitation, and because its subjective component is invisible to observers who assess only objective motor signs. Misidentification of akathisia as worsening psychosis, and the consequent dose escalation rather than dose reduction, is a well-documented clinical error that substantially worsens the patient's condition.2 Akathisia has been associated with dysphoria, anxiety, and in severe cases with suicidal ideation, making recognition and management urgent.
Akathisia occurs across all antipsychotic classes but is most common with high-potency FGAs and dose-dependent with most second-generation antipsychotics (SGAs). Among SGAs, it is particularly prominent with the partial D2 agonists aripiprazole and cariprazine at higher doses. Management options include dose reduction as the first and most effective intervention; switching to a lower-EPS agent (quetiapine, clozapine); propranolol 20 to 80 mg per day addressing the subjective restlessness component via beta-1 and beta-2 adrenergic blockade; mirtazapine 7.5 to 15 mg per day via 5-HT2A and 5-HT2C antagonism; lorazepam for short-term relief; and cyproheptadine as a second-line option.2 Anticholinergics are generally ineffective for akathisia, distinguishing its management from acute dystonia and drug-induced parkinsonism.
Drug-induced parkinsonism (DIP) presents with the classic triad of bradykinesia, rigidity, and tremor, indistinguishable at examination from idiopathic Parkinson's disease. It typically develops within days to weeks of initiating an antipsychotic or after dose escalation. DIP is the most common EPS syndrome in elderly patients, who have reduced baseline nigrostriatal DA reserve and are therefore more vulnerable to D2 blockade in the basal ganglia. Risk is proportional to D2 binding affinity and dose: high-potency FGAs carry the greatest risk, while quetiapine and clozapine at standard doses produce negligible DIP rates. The possibility that an antipsychotic is unmasking or accelerating subclinical Parkinson's disease rather than causing a purely drug-induced syndrome should be considered in older patients where DIP is unusually severe or fails to resolve fully after dose reduction or discontinuation.1
Management of DIP involves dose reduction as the primary intervention, switching to a lower-potency or faster-dissociating agent (quetiapine preferred in older patients and those with co-occurring Parkinson's disease), or adding an anticholinergic agent (benztropine, trihexyphenidyl) if dose reduction is not feasible. Anticholinergics are more effective for DIP than for akathisia and substantially reduce tremor and rigidity. However, anticholinergic agents carry their own burden, particularly in elderly patients, including cognitive impairment, urinary retention, constipation, dry mouth, and blurred vision; their benefit-risk ratio must be assessed individually. Amantadine is an alternative that acts via dopaminergic and glutamatergic mechanisms and is sometimes preferred in patients where anticholinergic adverse effects are a concern.1
Tardive dyskinesia (TD) is a hyperkinetic movement disorder characterized by repetitive, involuntary, purposeless movements, most prominently affecting the orofacial region (lip smacking, tongue protrusion, chewing movements, grimacing), though choreiform movements of the limbs and trunk also occur and may be the dominant presentation in some patients. It is definitionally a late complication of antipsychotic exposure, typically emerging after months to years of treatment, and may persist indefinitely after drug discontinuation, distinguishing it categorically from the reversible acute EPS syndromes.3
The prevailing pathophysiological model implicates compensatory postsynaptic dopamine D2 receptor upregulation in the striatum in response to sustained D2 blockade. Chronic receptor blockade produces denervation supersensitivity, increasing the number and sensitivity of striatal D2 receptors. When antipsychotic levels transiently fall (between doses, after dose reduction, or upon discontinuation), the supersensitized receptors are activated by endogenous DA, producing hyperkinetic movements. Supporting evidence includes the well-documented phenomenon of withdrawal-emergent TD, in which the dyskinesia first appears or worsens when the antipsychotic is reduced or stopped, and the temporary (and paradoxically counterproductive) suppression of TD movements by antipsychotic dose increases, which restores blockade but worsens the underlying supersensitivity.3
Risk factors for TD include cumulative duration and dose of antipsychotic exposure, older age, female sex, African American ethnicity, prior acute EPS, cognitive impairment, and the presence of a mood disorder as an indication for antipsychotic use (mood disorder patients appear to be at higher risk than schizophrenia patients at equivalent exposures). SGAs produce TD at substantially lower rates than FGAs, estimated at approximately 0.5 to 1% per year with SGAs compared with 4 to 8% per year with FGAs at standard doses, though risk is not zero for any agent that blocks D2 receptors at clinically meaningful occupancy levels. Clozapine, by virtue of its low and fast-dissociating D2 occupancy, appears to have the lowest TD liability of any antipsychotic and may even suppress existing TD in patients switched from other agents.3
Vesicular monoamine transporter 2 (VMAT2) inhibitors represent the first class of medications with regulatory approval specifically for TD. VMAT2 is the transporter responsible for packaging dopamine, serotonin, and norepinephrine into synaptic vesicles; inhibition depletes vesicular DA stores and reduces presynaptic DA release, thereby reducing the amount of DA available to activate the supersensitized striatal D2 receptors that drive hyperkinetic movements. Two VMAT2 inhibitors are approved by the Food and Drug Administration (FDA) for TD: valbenazine (Ingrezza) and deutetrabenazine (Austedo).4
Valbenazine is a selective VMAT2 inhibitor approved in 2017 for adults with TD. It is administered once daily at 40 mg for the first week, then 80 mg once daily thereafter; patients who do not tolerate 80 mg may continue at 40 mg. The pivotal KINECT 3 trial demonstrated significant reduction in Abnormal Involuntary Movement Scale (AIMS) scores versus placebo over 12 weeks, with a meaningful proportion of patients achieving clinically meaningful improvement or response.4 Valbenazine is metabolized by CYP3A4 to its active monohydrolyzed metabolite; strong CYP3A4 inhibitors raise valbenazine levels and require dose reduction. Adverse effects include somnolence, the most common dose-dependent effect, QTc prolongation (modest, requiring caution in patients with baseline QTc prolongation or QTc-active comedications), and the theoretical risk of worsening depression or suicidality shared with the VMAT2 inhibitor class, warranting monitoring in patients with co-occurring depressive episodes.
Deutetrabenazine is a deuterium-substituted derivative of tetrabenazine, approved for both TD and chorea associated with Huntington's disease. The deuterium substitution slows CYP2D6-mediated metabolism compared with tetrabenazine, extending the effective half-life and enabling twice-daily rather than three-times-daily dosing, with a more favorable adverse effect profile than tetrabenazine for most patients. The AIM-TD trial demonstrated significant AIMS score reduction at 12 weeks.5 Adverse effects include somnolence, depression, insomnia, and the risk of depression and suicidal ideation that is a class effect of VMAT2 inhibitors; a contraindication shared with tetrabenazine is untreated depression and active suicidality. Both valbenazine and deutetrabenazine should be initiated and titrated slowly, with monitoring for depressive symptom emergence.
Neuroleptic malignant syndrome (NMS) is a rare, idiosyncratic, potentially life-threatening reaction to antipsychotic medications characterized by hyperthermia, muscle rigidity, autonomic instability, and altered consciousness. It occurs in approximately 0.01 to 0.02% of patients exposed to antipsychotics, is more common with high-potency FGAs but can occur with any D2-blocking agent, and typically develops within the first 2 weeks of initiating or significantly escalating an antipsychotic.6 The pathophysiology involves sudden, massive central D2 receptor blockade disrupting hypothalamic thermoregulation and initiating a self-amplifying cycle of muscle rigidity producing heat through myofibrillar ATP hydrolysis, hyperthermia impairing the calcium regulation required for muscle relaxation, and autonomic dysregulation driven by both hypothalamic disruption and peripheral sympathetic activation.
The clinical presentation of NMS evolves over 24 to 72 hours and requires the presence of all four cardinal features for a definitive diagnosis, though the syndrome may be suspected and treatment initiated on the basis of two or three features developing in a patient on antipsychotic therapy. The tetrad consists of hyperthermia (temperature above 38 degrees Celsius, typically above 40 degrees in severe cases); lead-pipe muscle rigidity, characteristically severe and generalized, distinguishing NMS from the selective, predominantly orofacial rigidity of neuroleptic-induced parkinsonism; autonomic instability, including tachycardia, labile blood pressure, diaphoresis, tachypnea, and urinary incontinence; and altered mental status ranging from confusion and agitation to stupor and coma.6 Laboratory abnormalities include elevated creatine kinase (CK) from rhabdomyolysis, which may be profoundly elevated (levels above 100,000 U/L in severe cases), leukocytosis, elevated liver transaminases, metabolic acidosis, and myoglobinuria threatening renal failure.
Management of NMS is primarily supportive and must be initiated immediately upon recognition: discontinue all antipsychotics and other dopamine-blocking agents (including metoclopramide and prochlorperazine if present), initiate aggressive cooling measures including cooling blankets, ice packs to major vessels, and cold intravenous (IV) fluids, provide vigorous IV fluid resuscitation to protect renal function from myoglobin precipitation, and monitor CK and renal function at least every 6 hours during the acute phase. Intensive care unit (ICU) admission is required for most cases. Specific pharmacological interventions include dantrolene, a direct-acting muscle relaxant that inhibits calcium release from the sarcoplasmic reticulum and thereby reduces muscle rigidity and heat production (loading dose 1 to 2.5 mg/kg IV, then 1 mg/kg every 6 hours up to 10 mg/kg per day); and bromocriptine or amantadine, DA agonists that partially restore dopaminergic tone at the hypothalamic and striatal level (bromocriptine 2.5 mg two to three times daily, titrated up).6 Benzodiazepines address agitation and reduce peripheral sympathetic tone without the risks of antipsychotic rechallenge. Resolution of NMS typically occurs over 1 to 2 weeks after discontinuing the offending agent, though prolonged courses following depot antipsychotic-associated NMS are well documented because the drug cannot be rapidly removed.
Rechallenge with an antipsychotic after NMS is controversial. When psychiatric symptoms require continued treatment, rechallenge may be necessary, but should be delayed for at least 2 weeks after full resolution of the NMS episode, should begin with the lowest possible dose of the agent with the lowest D2 affinity available (quetiapine or clozapine are preferred), and must involve close monitoring for early signs of NMS recurrence. The risk of recurrence with rechallenge is estimated at approximately 30% and is substantially lower when a different, lower-potency agent is used rather than the original offending drug.
Antipsychotic-induced metabolic syndrome encompasses weight gain, glucose dysregulation, dyslipidemia, and hypertension, collectively representing the most prevalent long-term adverse effect burden of the antipsychotic class. The mechanisms are primarily receptor-mediated: histamine H1 blockade increases appetite and reduces basal metabolic rate; serotonin 5-HT2C blockade impairs hypothalamic satiety signaling; and direct effects on insulin secretion and peripheral glucose uptake, independent of weight gain, occur particularly with clozapine and olanzapine.7 The clinical consequences extend well beyond cosmetic or comfort concerns: patients with schizophrenia already have substantially elevated rates of cardiovascular disease and diabetes mellitus compared with the general population, and antipsychotic-induced metabolic syndrome further compounds these risks, contributing meaningfully to the 15 to 25-year reduction in life expectancy documented in this population relative to age-matched controls.
Systematic monitoring is the standard of care for all patients on any antipsychotic, regardless of perceived metabolic risk. Baseline assessment before initiating any antipsychotic should include weight and body mass index (BMI), waist circumference, blood pressure, fasting plasma glucose or hemoglobin A1c (HbA1c), and a fasting lipid panel. Follow-up weight should be assessed at 4, 8, and 12 weeks after initiation, with fasting glucose and lipids repeated at 12 weeks and then annually. Any patient who gains more than 5% of baseline body weight at any monitoring point warrants a clinical response: dietary counseling, exercise referral, and consideration of pharmacological intervention or antipsychotic switch.7
The most effective strategy for managing antipsychotic-induced metabolic syndrome is switching to a metabolically more favorable agent when the clinical situation permits. Switching from olanzapine or clozapine to aripiprazole, lurasidone, or ziprasidone consistently produces weight loss, improved insulin sensitivity, and favorable lipid changes in randomized trials, though the trade-off between metabolic improvement and potential loss of antipsychotic efficacy must be assessed for each patient.8 When a switch is not feasible because of superior efficacy of the current agent, pharmacological adjuncts have meaningful evidence: metformin (500 to 1000 mg twice daily) has the strongest evidence base in randomized trials, producing mean weight reductions of 2 to 3 kg and improvements in insulin sensitivity; it is generally well tolerated in antipsychotic-treated populations and is the recommended first-line pharmacological adjunct for antipsychotic-induced weight gain when a switch is not possible.8 Topiramate has also demonstrated efficacy in some trials but carries cognitive adverse effects, including word-finding difficulties and concentration impairment, that are particularly burdensome in patients with schizophrenia. Naltrexone/bupropion and liraglutide have emerging evidence but are not yet standard of care in this population. Aripiprazole augmentation of clozapine or olanzapine regimens produces modest weight attenuation through hypothalamic dopaminergic mechanisms and is used clinically, though the magnitude of benefit varies.
New-onset type 2 diabetes mellitus and glucose dysregulation occur at rates substantially above baseline in patients on clozapine and olanzapine, and at lower but still elevated rates with quetiapine and risperidone. The mechanism involves both weight-mediated insulin resistance and direct pancreatic beta-cell effects reducing insulin secretion, the latter mechanism being weight-independent and producing glucose abnormalities even in patients without significant weight gain. Diabetic ketoacidosis (DKA) has been reported with clozapine and olanzapine in patients without prior diabetes history. Fasting glucose monitoring at 12 weeks and annually is the minimum standard; in patients with established diabetes or prediabetes, quarterly monitoring and coordination with endocrinology or primary care for glucose management is appropriate. New-onset hyperglycemia in a patient on clozapine or olanzapine should prompt immediate dietary intervention and consideration of antipsychotic switch as well as pharmacological glucose management if indicated.7
Antipsychotics prolong the cardiac QTc interval through blockade of the rapidly activating delayed rectifier potassium current (IKr), reducing repolarization reserve and increasing the risk of torsades de pointes (TdP) arrhythmia, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death. QTc prolongation liability varies substantially across antipsychotics: thioridazine and pimozide carry the highest risk and are now rarely used for this reason; ziprasidone produces mean QTc prolongation of approximately 10 milliseconds (ms); haloperidol IV at high doses carries substantial QTc risk; iloperidone, amisulpride, and sertindole are intermediate; and clozapine, olanzapine, quetiapine, and risperidone carry low but nonzero risk.9 The partial agonists aripiprazole, brexpiprazole, and cariprazine produce negligible QTc prolongation.
The clinical threshold for concern is a QTc exceeding 500 ms or an increase from baseline of more than 60 ms, both of which substantially increase TdP risk. Risk is compounded by electrolyte abnormalities (hypokalemia and hypomagnesemia lower the threshold for TdP), bradycardia, congenital or acquired long QT syndrome, female sex (longer baseline QTc), advanced age, cardiac disease, and co-administration of other QTc-prolonging agents. A baseline electrocardiogram (ECG) is recommended before initiating any antipsychotic with meaningful QTc liability (particularly thioridazine, pimozide, ziprasidone, haloperidol IV, iloperidone), and repeat ECG should be obtained when adding a QTc-active co-medication, after dose escalation, or when electrolyte abnormalities are identified. Correction of electrolyte abnormalities before initiating or continuing antipsychotics with QTc liability is a mandatory and often overlooked intervention.9
Antipsychotic-induced hyperprolactinemia results from D2 blockade in the tuberoinfundibular dopaminergic pathway, removing the tonic inhibitory brake that endogenous DA exerts on prolactin secretion from the anterior pituitary lactotroph cells. Clinical consequences of sustained hyperprolactinemia include amenorrhea and menstrual irregularity, galactorrhea, sexual dysfunction in both sexes (reduced libido, erectile dysfunction, anorgasmia), gynecomastia in men, reduced bone mineral density with long-term exposure, and the potential for prolactinoma growth stimulation if a pre-existing microprolactinoma is present. Hyperprolactinemia is most pronounced and sustained with risperidone, paliperidone, and high-potency FGAs, and is essentially absent with clozapine, quetiapine, and partial agonists aripiprazole, brexpiprazole, and cariprazine, which provide enough D2 activation to partially preserve dopaminergic inhibition of prolactin secretion.1,10
Management of antipsychotic-induced hyperprolactinemia begins with measurement of a serum prolactin level to confirm the diagnosis and quantify severity. If the antipsychotic can be switched to a prolactin-sparing agent without compromising psychiatric stability, this is the most effective intervention; aripiprazole is often selected because its partial D2 agonism normalizes prolactin within weeks. Adding low-dose aripiprazole (5 to 15 mg per day) to an existing regimen of a prolactin-elevating antipsychotic (particularly risperidone or paliperidone) reduces prolactin levels substantially without requiring a full agent switch, an approach supported by several randomized trials.1 Cabergoline or bromocriptine can be used when a switch is not feasible, but their D2 agonist activity carries a theoretical risk of worsening psychosis and they should be used with caution and close psychiatric monitoring.
Antipsychotic-induced sedation is primarily mediated by H1 receptor blockade and, to a lesser degree, by alpha-1 adrenergic and muscarinic M1 receptor blockade. Sedation is most prominent with clozapine, quetiapine, olanzapine, and chlorpromazine, all of which have high H1 affinity. In acute psychosis, sedation may be therapeutically useful for reducing agitation, improving sleep, and calming behavioral disturbances; in the maintenance phase, persistent sedation impairs cognitive performance, occupational functioning, quality of life, and long-term medication adherence. Strategies for managing unwanted sedation include dose reduction, shifting the dose to bedtime if once-daily dosing permits, switching to a less sedating agent (aripiprazole, ziprasidone, lurasidone, or a low-dose risperidone formulation), and avoiding concurrent sedating medications (benzodiazepines, antihistamines, opioids) where possible. Modafinil and armodafinil have been studied as adjunctive agents to improve daytime alertness without worsening psychosis in some populations, though the evidence base is limited.1
Clozapine's adverse effect profile is qualitatively distinct from all other antipsychotics by virtue of several effects that are essentially unique to this agent. A systematic approach to anticipating, monitoring, and managing these effects is essential for any clinician prescribing clozapine, as they represent both the greatest barriers to initiation and the most common reasons for premature discontinuation in patients who would otherwise benefit from treatment-resistant schizophrenia (TRS) therapy.
Clozapine-induced agranulocytosis (absolute neutrophil count (ANC) below 500 cells per microliter) occurs in approximately 0.8 to 1% of patients, with peak risk in the first 3 to 6 months. The Risk Evaluation and Mitigation Strategy (REMS) program mandates ANC monitoring before each dispensing (weekly for 6 months, biweekly for months 6 to 12, monthly thereafter), and patient registration in the national REMS database. The mechanism involves both toxic metabolite-mediated direct neutrophil precursor damage and immune-mediated anti-neutrophil antibody production. Benign ethnic neutropenia (BEN), prevalent in patients of African, Middle Eastern, and Afro-Caribbean ancestry, produces lower baseline ANC values without increased infection risk; updated REMS guidelines provide BEN-adjusted monitoring thresholds to prevent inappropriate discontinuation. Any patient developing an ANC below 500 cells per microliter must have clozapine permanently discontinued; rechallenge is not permitted. Granulocyte colony-stimulating factor (G-CSF) is used as adjunctive treatment for severe agranulocytosis.11
Excessive salivation (sialorrhea) occurs in approximately 30 to 80% of clozapine-treated patients and is one of the most common reasons for patient distress and dose limitation. The mechanism is paradoxical: despite clozapine's significant muscarinic M1 antagonism (which would be expected to reduce salivation), sialorrhea occurs because clozapine acts as an agonist at the M4 receptor subtype in the submandibular glands, stimulating salivation through a receptor-subtype-specific mechanism. Management options include glycopyrrolate, an anticholinergic that does not cross the blood-brain barrier (avoiding central anticholinergic effects) and can be given orally or sublingually; ipratropium nasal spray directed into the mouth; low-dose clonidine (an alpha-2 agonist that reduces salivary gland secretion via sympathetic-independent pathways); and benzatropine, though systemic anticholinergics increase the risk of cognitive impairment and ileus at higher doses. Nocturnal sialorrhea specifically may be managed with hyoscine (scopolamine) transdermal patches applied at bedtime.
Clozapine lowers the seizure threshold in a dose-dependent manner, with seizure rates estimated at approximately 1 to 2% at doses below 300 mg per day, rising to approximately 5% or above at doses exceeding 600 mg per day. The mechanism involves clozapine's ability to increase cortical neuronal excitability, possibly through modulation of GABAergic inhibitory interneuron function and glutamatergic pathways. Clozapine-associated seizures are most common during rapid dose titration and at peak plasma concentrations. When a patient on clozapine develops a seizure, the first response is to exclude other causes (electrolyte abnormalities, metabolic disturbances, withdrawal states), reduce clozapine dose if possible, and assess whether an antiepileptic drug (AED) is needed. Valproate is the most commonly added AED in this context because it has the additional benefit of mood stabilization in patients with schizoaffective disorder and does not significantly affect clozapine plasma levels; carbamazepine is contraindicated with clozapine due to the additive bone marrow suppression risk and the CYP enzyme induction effect reducing clozapine levels. Lamotrigine is a reasonable alternative AED that is metabolically neutral and does not interact pharmacokinetically with clozapine.11
Clozapine-induced myocarditis is a rare but potentially fatal complication occurring predominantly in the first 6 to 8 weeks of treatment, with an estimated incidence of 0.1 to 1% in most registries, though rates up to 3% have been reported in Australian databases where surveillance is most systematic. The mechanism is incompletely understood but likely involves IgE-mediated hypersensitivity reactions to clozapine metabolites producing myocardial inflammation. Clinical presentation may include fever, chest pain, dyspnea, tachycardia, and elevation of cardiac biomarkers (troponin, CRP); in some cases progression to cardiomyopathy or fulminant cardiac failure can occur. Baseline troponin and C-reactive protein (CRP) measurement before initiating clozapine, with weekly monitoring for the first 4 weeks and at any development of cardiac symptoms, is recommended by Australian and some European guidelines; US guidelines are less prescriptive but monitoring is reasonable given the severity of the complication.11 If myocarditis is suspected, clozapine should be discontinued immediately, cardiology consultation obtained, and rechallenge is generally contraindicated. Clozapine also causes orthostatic hypotension through alpha-1 adrenergic blockade, particularly prominent during initiation and requiring a slow titration schedule starting at 12.5 mg once or twice daily.
Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge: Cambridge University Press; 2013:129–237.
Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627–643.
doi:10.4088/JCP.08r04210Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425.
doi:10.1176/appi.ajp.161.3.414Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484.
doi:10.1176/appi.ajp.2017.16091037Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604.
doi:10.1016/S2215-0366(17)30236-5Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–876.
doi:10.1176/ajp.2007.164.6.870De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.
doi:10.1038/nrendo.2011.156Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev. 2012;8(1):25–36.
doi:10.2174/157340012798994867Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774–1782.
doi:10.1176/appi.ajp.158.11.1774Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11(1):59–67.
doi:10.1016/j.coph.2011.02.007Citrome L. Clozapine for schizophrenia: life-threatening or life-saving treatment? Curr Psychiatry. 2009;8(12):56–63. [REMS monitoring, agranulocytosis management, and clozapine-specific adverse effects]